LVW Advisors’s Anebulo Pharmaceuticals ANEB Stock Holding History

LVW Advisors’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-349,617	Closed	-$503K	–	351
2025 Q2	$503K	Hold	349,617	–	–	0.05%	190
2025 Q1	$455K	Sell	349,617 -282,899	-45%	-$416K	0.05%	187
2024 Q4	$1.06M	Sell	632,516 -8,523	-1%	-$14K	0.13%	104
2024 Q3	$1.24M	Sell	641,039 -1,000	-0.2%	-$2.13K	0.16%	96
2024 Q2	$1.75M	Hold	642,039	–	–	0.26%	60
2024 Q1	$1.84M	Sell	642,039 -1,000	-0.2%	-$2.57K	0.31%	55
2023 Q4	$1.56M	Sell	643,039 -29,292	-4%	-$68.9K	0.29%	57
2023 Q3	$2.05M	Hold	672,331	–	–	0.42%	51
2023 Q2	$1.58M	Sell	672,331 -1,000	-0.1%	-$2.5K	0.3%	71
2023 Q1	$1.95M	Sell	673,331 -583	-0.1%	-$1.66K	0.38%	61
2022 Q4	$1.63M	Sell	673,914 -1,050	-0.2%	-$2.77K	0.33%	70
2022 Q3	$1.89M	Sell	674,964 -25,036	-4%	-$88.9K	0.42%	61
2022 Q2	$3.64M	Buy	+700,000	New	+$2.93M	0.74%	38

Other funds holding ANEB

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LVW Advisors's ANEB Position: Q3 2025 in Review

LVW Advisors sold out of Anebulo Pharmaceuticals (ANEB) in Q3 2025, closing a stake of 349,617 shares — an estimated $503K sold.

LVW Advisors first reported a position in ANEB in Q2 2022 and held it in 13 quarters. The position peaked at $3.64M in Q2 2022. 21 funds tracked by Wall St. Rank hold ANEB as of Q3 2025.

LVW Advisors reported no remaining Anebulo Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
LVW Advisors sold 349,617 Anebulo Pharmaceuticals shares in Q3 2025, an estimated $503K.
LVW Advisors first reported a position in Anebulo Pharmaceuticals in Q2 2022 and held it in 13 quarters.
LVW Advisors's Anebulo Pharmaceuticals position peaked at $3.64M in Q2 2022.
21 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q3 2025.

Based on LVW Advisors's 13F filing for Q3 2025, filed 20 Oct 2025.